Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)

ESMO Open. 2016 May 17;1(3):e000049. doi: 10.1136/esmoopen-2016-000049. eCollection 2016.

¹ Department of Oncology and Nuclear Medicine , University Hospital Center Sestre Milosrdnice , Zagreb , Croatia.
² Hospital Center Emile Mayrisch , Esch-sur-Alzette , Luxemburg.

No abstract available

Keywords: long term hormone therapy efficacy; metastatic castration-resistant prostate cancer (mCRPC).